Latest GeoVax News
GeoVax to Conduct Investor and Partnering Meetings During J.P. Morgan 36th Annual Healthcare Conference
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is scheduling investor and corporate partnering meetings during the J.P. Morgan 36th Annual Healthcare Conference, to be held in San Francisco on January 8-11, 2018.
Senior management of GeoVax will be available for one-on-one meetings with investment professionals and business development representatives from the life sciences industry. The Company will provide an update on its vaccine development programs in the areas of HIV, Zika, Lassa fever, malaria, hepatitis B immunotherapy, and immuno-oncology.
Robert McNally, PhD, GeoVax’s President & CEO, commented, “We look forward to a full schedule during the upcoming conference as we seek collaborators, partners and investors to advance multiple programs toward human clinical trials. Our HIV clinical program continues to progress with NIH support, and we are building an impressive preclinical data set for our other pipeline programs, supporting the rationale for investment in additional clinical activities. Recognizing the importance of Asian markets and the longer-term thinking of Asian investors, we also intend to make a concerted effort to reach out to China-based investors and pharmaceutical companies who see the strategic value of a relationship with GeoVax.”
Interested parties may schedule meetings with GeoVax through the conference websites for the Biotech Showcase (https://ebdgroup.knect365.com/biotech-showcase/), the Redefining Early Stage Investments (RESI) Conference (http://www.resiconference.com/), or through the partnering system hosted by the Biotechnology Innovation Organization (http://convention.bio.org/partner/). Non-conference meetings may also be scheduled by contacting Company management directly.
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company’s HIV vaccine for the clade B epidemic in the Americas, Australia, Japan and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network (HVTN). Preclinical programs are focused on preventive vaccines for Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic hepatitis B infections and cancers. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and effectively stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.